Translational Biomedicine

  • ISSN: 2172-0479
  • Journal h-index: 18
  • Journal CiteScore: 5.91
  • Journal Impact Factor: 4.11
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Open J Gate
  • Genamics JournalSeek
  • JournalTOCs
  • ResearchBible
  • The Global Impact Factor (GIF)
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Proquest Summons
  • Publons
  • MIAR
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Editorial - (2020) Volume 11, Issue 3

Editorial note for Translational Oncolgy

Mahmoud M*

Department of Radiation Oncology, National Cancer Institute, Cairo University, Egypt

Corresponding Author:
Mahmoud M
Department of Radiation Oncology
National Cancer Institute, Cairo University, Egypt
Tel: + 201001536681

Received Date: July 15, 2020; Accepted Date: July 20, 2020; Published Date: July 27, 2020

Citation: Mahmoud M (2020) Editorial Note for Translational Biomedicine. Transl Biomed. Vol.11 No.3:7 DOI: 10.36648/2172-0479.11.3.170

Copyright: © 2020 Mahmoud M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Translational Biomedicine

Editorial Note

Translational Biomedicine (IPTB) is an international open access, peer-reviewed academic journal publishing scholarly research articles, case reports, comprehensive/mini reviews and short communications from basic sciences to clinical sciences at a bimonthly frequency. The Translational Biomedicine issue being vast, deep and multidisciplinary in nature, an abstract perspective of the current and trending research and scholarly activities becomes important for effective transformation into health and research collaborations. The Journal aims to cater into the original science-based research that gains the momentum of communication between the scientific discovery and health improvement. This editorial compiles down the scientific breakthrough in the Translational Oncology domain published by the journal and reflects their overall impact and relevance for evaluating new treatment paradigms for Cancer.

Giuseppe Di Bella et al. [1] studied Over-Expression of GH/GHR in Breast Cancer and Oncosuppressor Role of Somatostatin as a Physiological Inhibitor with the reports emphasizing increased expression of the mitogenic GH (Growth Hormone)/IGF1 (Insulin- Like Growth Factor) axis in tumor tissues compared to healthy tissues, with a directly proportional dose-dependent relationship between GH/IGF1, proliferative index and invasive ability in numerous types of tumors. The authors evaluated the levels of GH and GHR in 39 cases of breast cancer, divided according to different risk levels on the basis of immunohistochemical and histological tests with nuclear grade. The scientific evidence provides the rationale for using somatostatin/ octreotide in combined oncotherapy. The intention of authors contributed in improving the prognosis in the specific case of breast cancer, which still represents, throughout the world, the leading cause of death in women.

Yang Wang et al. [2] reported Non-small cell lung cancer (NSCLC) and which accounts for more than 80% of the total lung cancer. The gemcitabine-based chemotherapy is the first-line therapeutic approach for the NSCLC treatment but it still remains poor among the NSCLC patients. The role of TRIM22 was significantly upregulated in GEM-resistant lung adenocarcinoma cell line A549 which is negatively transcriptional regulated by FOXO3. Additionally, TRIM22 promoted GEM-induced pro-survival autophagy to protected NSCLC cells from apoptosis.

Hemeda R et al. [3] correlated Obesity with the increase in the risk of breast cancer mortality by taking into consideration about the higher levels of aromatase enzyme activity. The usage of Adjuvant Aromatase inhibitors in postmenopausal women with early breast cancer led to significant reduction in serum estradiol levels; thus crafting it an effective treatment.

Research investigations in the scholarly articles bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients.



  1. Bella GD, Scanferlato R, Colori B (2018) Over-Expression of GH/GHR in Breast Cancer and Oncosuppressor Role of Somatostatin as a Physiological Inhibitor. Transl Biomed 9: 1-10.
  2. Wang Y, Liang H, Zhang C, Zou M, Zou B, et al. (2019) TRIM22 Abated the Antitumor Effect of Gemcitabine in Non-small Cell Lung Cancer via Autophagy Induction. Transl Biomed 10: 1-10.
  3. Hemeda R, Sarhan A, Sawy WE, Aidaros M, Gharib A, et al. (2019) Effect of Obesity on Treatment Outcome in Postmenopausal Women with Breast Cancer under Adjuvant Aromatase Inhibitors. Transl Biomed 10: 11-20.